Highlights

  • Neurizon Therapeutics (ASX:NUZ) completed enrolment of 250 participants across 78 activated U.S. clinical sites in Regimen I of the HEALEY ALS Platform Trial.
  • Topline efficacy and safety results from the NUZ-001 HEALEY study are expected in late Q2 CY2027.
  • An NIH-funded Expanded Access Program is expected to provide NUZ-001 access to up to 200 people with ALS in the United States for up to 96 weeks.
  • At the time of writing this article, Neurizon Therapeutics (ASX:NUZ) was trading at AUD 0.089, up 5.95% during today’s trading session.

At the time of writing this article, Neurizon Therapeutics (ASX:NUZ) was trading at AUD 0.089, up 5.95% during today’s trading session. Neurizon Therapeutics is an Australian clinical-stage biotechnology company developing therapies for neurodegenerative diseases. Its main development program centres on NUZ-001, also known as S-Monepantel, which is being evaluated for amyotrophic lateral sclerosis, the most common form of motor neurone disease. Recent developments have focused on completion of enrolment in the HEALEY ALS Platform Trial, establishment of an expanded access pathway and preparation for the next clinical data milestone.

Company Business

Neurizon’s development strategy is centred on NUZ-001, an investigational therapy being assessed across neurodegenerative disease indications. The company’s initial clinical focus is ALS, a progressive neurological disorder that affects nerve cells responsible for voluntary muscle movement.

NUZ-001 has completed a Phase 1 study and a subsequent 12-month open-label extension study in a small cohort of people with ALS. The company reported that treatment appeared generally well tolerated during those studies, while exploratory measures included survival, functional decline and respiratory outcomes. The asset has since progressed into Regimen I of the HEALEY ALS Platform Trial, an adaptive Phase 2/3 study being conducted in the United States.

Neurizon is also evaluating the potential application of NUZ-001 across other neurodegenerative conditions while maintaining ALS as its principal clinical program.

Recent Development

A central development in 2026 was completion of enrolment in Regimen I of the HEALEY ALS Platform Trial. The study enrolled 250 participants across 78 activated clinical sites in the United States. Neurizon said enrolment was completed in less than five months following first dosing, allowing the expected timing for topline efficacy and safety results to move to late Q2 CY2027.

In September 2026, Neurizon also announced that the U.S. National Institutes of Health had funded an Expanded Access Program for NUZ-001. The program is intended for people with ALS who are otherwise unable to participate in Clinical Trials and is expected to provide access to up to 200 patients for as long as 96 weeks. Neurizon will Supply NUZ-001 and act as regulatory sponsor, while the program will be led through the HEALEY ALS clinical infrastructure.

The company also progressed its management structure during the period, appointing Dr Chris Bremer as Chief Executive Officer. He formally commenced in the role in early October 2026.

Financial Performance and Sector Context

For FY2026, Neurizon remained a clinical-stage biotechnology company without a commercialised drug product. The company reported a net loss after tax of approximately AUD 10.72 million for the year ended 30 June 2026, compared with approximately AUD 16.59 million in FY2025.

Cash and cash equivalents were approximately AUD 12.69 million at 30 June 2026, compared with AUD 4.16 million a year earlier. Net Assets increased to approximately AUD 12.73 million from AUD 2.82 million at the end of FY2025.

The company has also used financing arrangements to support clinical development. During 2026, it entered an R&D financing Facility and subsequently completed an initial drawdown under that facility. Neurizon also announced a partial Redemption of convertible notes in September as part of its capital-management activities.

For biotechnology companies at this stage of development, expenditure is generally concentrated on clinical trials, regulatory work, manufacturing, personnel and intellectual property rather than commercial sales operations.

Risks to Consider

Neurizon remains exposed to clinical development risk because NUZ-001 has not been approved for commercial use in any jurisdiction. Trial outcomes may differ from earlier exploratory results, while regulatory authorities can require additional studies, Manufacturing work or supporting data before permitting further development or commercialisation.

Other considerations include clinical trial execution, patient follow-up, manufacturing consistency, intellectual property protection and future funding requirements. The company’s financial performance also remains dependent on maintaining sufficient Capital while its clinical programs progress.

What to Watch Next

The primary upcoming milestone is the release of topline efficacy and safety results from Regimen I of the HEALEY ALS Platform Trial, currently expected in late Q2 CY2027.

Investors may also monitor the commencement and enrolment of the NIH-funded Expanded Access Program, progress with regulatory engagement and any additional clinical information generated from NUZ-001 treatment.

Manufacturing readiness and funding will remain relevant as the company approaches later-stage regulatory decisions. Neurizon has also secured a five-year supply agreement covering GMP monepantel, the active pharmaceutical ingredient used in NUZ-001, supporting longer-term clinical and manufacturing requirements.

Key Insights

Neurizon Therapeutics enters the next phase of its NUZ-001 program with HEALEY ALS enrolment completed and 250 participants involved across 78 U.S. clinical sites. The company has also added an NIH-funded Expanded Access Program that could provide treatment access to as many as 200 additional ALS patients.

Financially, Neurizon ended FY2026 with higher cash and net assets than a year earlier, while continuing to report a net loss consistent with its clinical-development stage. Attention is now centred on execution of the ongoing study, the expanded access program, capital management and the anticipated late-Q2 CY2027 HEALEY topline results.